首页 › 淋巴瘤 › 加利福尼亚州 › Baldwin Park
Baldwin Park CA 淋巴瘤临床试验
22项针对 淋巴瘤的研究正在 Baldwin Park及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
HPC Offered for PRESERVE Expansion
招募中观察性研究
- City of Hope, Duarte · 距离 4 英里
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
招募中3 期
- City of Hope Cancer Center, Duarte · 距离 4 英里
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
招募中观察性研究欢迎健康志愿者
- City of Hope, Duarte · 距离 4 英里
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
招募中2 期
- City of Hope, Duarte · 距离 4 英里
Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)
招募中1 期
- City of Hope Medical Center, Duarte · 距离 4 英里
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
招募中2 期
- City of Hope Medical Center, Duarte · 距离 4 英里
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
招募中1/2 期
- City of Hope, Duarte · 距离 4 英里
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
招募中1 期
- City of Hope, Duarte · 距离 4 英里
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
招募中1/2 期
- Research Site, Duarte · 距离 4 英里
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
招募中1/2 期
- City of Hope, Duarte · 距离 4 英里
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
招募中1 期
- City of Hope Medical Foundation, Duarte · 距离 4 英里
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
招募中1 期
- City of Hope, Duarte · 距离 4 英里
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
招募中1 期
- City of Hope, Duarte · 距离 4 英里
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
招募中1/2 期
- City of Hope National Medical Center, Duarte · 距离 4 英里
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
招募中1/2 期
- City of Hope, Duarte · 距离 4 英里
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- City of Hope, Duarte · 距离 4 英里
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
招募中1/2 期
- Dren Investigational Site, Duarte · 距离 4 英里
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
招募中观察性研究
- City of Hope Comprehensive Cancer Center, Duarte · 距离 4 英里
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
招募中1/2 期
- City of Hope, Duarte · 距离 4 英里
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
招募中2 期
- City of Hope National Medical Center, Duarte · 距离 4 英里
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- City of Hope, Duarte · 距离 4 英里
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
招募中2 期
- City of Hope, Duarte · 距离 4 英里
其他城市的 淋巴瘤试验
- Houston, TX34 项研究
- Boston, MA34 项研究
- New York City, NY33 项研究
- Washington, DC23 项研究
- Chicago, IL19 项研究
- Durham, NC17 项研究
- St. Louis, MO15 项研究
- Cleveland, OH13 项研究
- Seattle, WA13 项研究
- Atlanta, GA13 项研究
- Philadelphia, PA13 项研究
- Edison, NJ12 项研究
Baldwin Park的其他研究
- 乳腺癌43 项研究
- 急性髓系白血病41 项研究
- 结直肠癌37 项研究
- 非小细胞肺癌36 项研究
- 癌症（所有类型）34 项研究
- 前列腺癌31 项研究
- 转移性癌症30 项研究
- 卵巢癌27 项研究
- 骨髓增生异常综合征27 项研究
- 肺癌23 项研究
- 多发性骨髓瘤23 项研究
- 急性淋巴细胞白血病21 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年11月15日。每项研究自行设定入选标准，由研究团队决定谁能参与。